Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains

European Journal of Medicinal Chemistry

Volumn 53, Issue , 2012, Pages 292-299

  Wang, Shengzheng ^a   Jin, Gang ^b   Wang, Wenya ^a   Zhu, Lingjian ^a   Zhang, Yongqiang ^a   Dong, Guoqiang ^a   Liu, Yang ^a   Zhuang, Chunlin ^a   Miao, Zhenyuan ^a   Yao, Jianzhong ^a   Zhang, Wannian ^a   Sheng, Chunquan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antifungal activity; Azole; Molecular docking; Structure activity relationship

Indexed keywords

1 [[3 (4 BROMOPHENOXY)PROPYL](4 FLUOROBENZYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](4 METHYLBENZYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](BUTYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](ETHYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](ISOBUTYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](PROP 2 YN 1 YL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [[3 (4 BROMOPHENOXY)PROPYL](PROPYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [ALLYL(3 PHENOXYPROPYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [ALLYL[3 (4 BROMOPHENOXY)PROPYL]AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [BENZYL(3 PHENOXYPROPYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [BENZYL[3 (4 BROMOPHENOXY)PROPYL]AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1 [BUTYL(3 PHENOXYPROPYL)AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 1[[3 (4 BROMOPHENOXY)PROPYL]AMINO] 2 (2,4 DIFLUOROPHENYL) 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [(3 PHENOXYPROPYL)(PROP 2 YN 1 YL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [(3 PHENOXYPROPYL)(PROPYL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [(3 PHENOXYPROPYL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [(4 FLUOROBENZYL)(3 PHENOXYPROPYL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [(4 METHYLBENZYL)(3-PHENOXYPROPYL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; 2 (2,4 DIFLUOROPHENYL) 1 [ETHYL(3 PHENOXYPROPYL)AMINO] 3 (1H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; ANTIFUNGAL AGENT; ETHYL 2 [[2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL](3 PHENOXYPROPYL)AMINO]ACETATE; ETHYL 2 [[3 (4 BROMOPHENOXY)PROPYL][2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL]AMINO]ACETATE; FLUCONAZOLE; ITRACONAZOLE; METHYL 2 [[2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL](3 PHENOXYPROPYL)AMINO]ACETATE; METHYL 2 [[3 (4 BROMOPHENOXY)PROPYL][2 (2,4 DIFLUOROPHENYL) 2 HYDROXYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL]AMINO]ACETATE; TERT BUTYL 2 [[2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL](3 PHENOXYPROPYL)AMINO]ACETATE; TERT BUTYL 2 [[3 (4 BROMOPHENOXY)PROPYL][2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL]AMINO]ACETATE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; STRUCTURE ACTIVITY RELATION; SYSTEMIC MYCOSIS; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; FUNGI; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; NITROGEN; PROPYLAMINES; PROTEIN CONFORMATION; STEROL 14-DEMETHYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84861622305     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.04.013     Document Type: Article

References (41)

1. Y. Aoyama, Y. Yoshida, and R. Sato Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes J. Biol. Chem. 259 1984 1661 1666
2. M.T. Fera, E. La Camera, and A. De Sarro New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7 2009 981 998
3. S.L. Kelly, D.C. Lamb, B.C. Baldwin, A.J. Corran, and D.E. Kelly Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents J. Biol. Chem. 272 1997 9986 9988
4. R. Cha, and J.D. Sobel Fluconazole for the treatment of candidiasis: 15 years experience Expert Rev. Anti Infect. Ther. 2 2004 357 366
5. I.A. Casalinuovo, P. Di Francesco, and E. Garaci Fluconazole resistance in Candida albicans: a review of mechanisms Eur. Rev. Med. Pharmacol. Sci. 8 2004 69 77
6. H.L. Hoffman, E.J. Ernst, and M.E. Klepser Novel triazole antifungal agents Expert Opin. Investig. Drugs 9 2000 593 605
7. P.H. Chandrasekar, and E. Manavathu Voriconazole: a second-generation triazole Drugs Today (Barc) 37 2001 135 148
8. R. Herbrecht Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections Int. J. Clin. Pract. 58 2004 612 624
9. S. Arikan, and J.H. Rex Ravuconazole Eisai/Bristol-Myers Squibb Curr. Opin. Investig. Drugs 3 2002 555 561
10. J. Capilla, C. Yustes, E. Mayayo, B. Fernandez, M. Ortoneda, F.J. Pastor, and J. Guarro Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits Antimicrob. Agents Chemother. 47 2003 1948 1951
11. M. Niimi, N.A. Firth, and R.D. Cannon Antifungal drug resistance of oral fungi Odontology 98 2010 15 25
12. E. Snelders, W.J. Melchers, and P.E. Verweij Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 6 2011 335 347
13. R.A. Akins An update on antifungal targets and mechanisms of resistance in Candida albicans Med. Mycol. 43 2005 285 318
14. G. Ramage, S.P. Saville, D.P. Thomas, and J.L. Lopez-Ribot Candida biofilms: an update Eukaryot. Cell 4 2005 633 638
15. R. Guillon, F. Pagniez, F. Giraud, D. Crepin, C. Picot, M. Le Borgne, F. Morio, M. Duflos, C. Loge, and P. Le Pape Design, synthesis, and in vitro antifungal activity of 1-[(4-substituted-benzyl)methylamino]-2-(2,4- difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols ChemMedChem 6 2011 816 825
16. R. Guillon, F. Pagniez, C. Rambaud, C. Picot, M. Duflos, C. Loge, and P. Le Pape Design, synthesis, and biological evaluation of 1-[(biarylmethyl) methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as potent antifungal agents: new insights into structure-activity relationships ChemMedChem 6 2011 1806 1815
17. Y. Jiang, Y. Cao, J. Zhang, Y. Zou, X. Chai, H. Hu, Q. Zhao, Q. Wu, D. Zhang, and Q. Sun Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1, 2,4-triazol-5(4H)-one Eur. J. Med. Chem. 46 2011 3135 3141
18. R. Guillon, C. Loge, F. Pagniez, V. Ferchaud-Roucher, M. Duflos, C. Picot, and P. Le Pape Synthesis and in vitro antifungal evaluation of 2-(2,4-difluorophenyl)-1-[(1H-indol-3-ylmethyl)methylamino]-3-(1H-1,2,4-tr iazol-1-yl)propan-2-ols J. Enzyme Inhib. Med. Chem. 26 2011 261 269
19. R. Guillon, F. Giraud, C. Loge, M. Le Borgne, C. Picot, F. Pagniez, and P. Le Pape Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols Bioorg. Med. Chem. Lett. 19 2009 5833 5836
20. C. Sheng, X. Che, W. Wang, S. Wang, Y. Cao, J. Yao, Z. Miao, and W. Zhang Structure-based design, synthesis, and antifungal activity of new triazole derivatives Chem. Biol. Drug Des. 78 2011 309 313
21. W. Wang, S. Wang, Y. Liu, G. Dong, Y. Cao, Z. Miao, J. Yao, W. Zhang, and C. Sheng Novel conformationally restricted triazole derivatives with potent antifungal activity Eur. J. Med. Chem. 45 2010 6020 6026
22. X. Chai, J. Zhang, Y. Cao, Y. Zou, Q. Wu, D. Zhang, Y. Jiang, and Q. Sun Design, synthesis and molecular docking studies of novel triazole as antifungal agent Eur. J. Med. Chem. 46 2011 3167 3176
23. W. Wang, C. Sheng, X. Che, H. Ji, Z. Miao, J. Yao, and W.N. Zhang Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives Arch. Pharm. (Weinheim) 342 2009 732 739
24. W. Wang, C. Sheng, X. Che, H. Ji, Y. Cao, Z. Miao, J. Yao, and W. Zhang Discovery of highly potent novel antifungal azoles by structure-based rational design Bioorg. Med. Chem. Lett. 19 2009 5965 5969
25. C. Sheng, W. Wang, X. Che, G. Dong, S. Wang, H. Ji, Z. Miao, J. Yao, and W. Zhang Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization ChemMedChem 5 2010 390 397
26. C. Sheng, W. Zhang, H. Ji, M. Zhang, Y. Song, H. Xu, J. Zhu, Z. Miao, Q. Jiang, J. Yao, Y. Zhou, and J. Lu Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking J. Med. Chem. 49 2006 2512 2525
27. X. Chai, J. Zhang, H. Hu, S. Yu, Q. Sun, Z. Dan, Y. Jiang, and Q. Wu Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase Eur. J. Med. Chem. 44 2009 1913 1920
28. Z. Guan, X. Chai, S. Yu, H. Hu, Y. Jiang, Q. Meng, and Q. Wu Synthesis, molecular docking, and biological evaluation of novel triazole derivatives as antifungal agents Chem. Biol. Drug Des. 76 2010 496 504
29. H. Ji, W. Zhang, Y. Zhou, M. Zhang, J. Zhu, Y. Song, and J. Lu A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals J. Med. Chem. 43 2000 2493 2505
30. C. Sheng, W. Zhang, M. Zhang, Y. Song, H. Ji, J. Zhu, J. Yao, J. Yu, S. Yang, Y. Zhou, and J. Lu Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions J. Biomol. Struct. Dyn. 22 2004 91 99
31. X. Che, C. Sheng, W. Wang, Y. Cao, Y. Xu, H. Ji, G. Dong, Z. Miao, J. Yao, and W. Zhang New azoles with potent antifungal activity: design, synthesis and molecular docking Eur. J. Med. Chem. 44 2009 4218 4226
32. Y. Xu, C. Sheng, W. Wang, X. Che, Y. Cao, G. Dong, S. Wang, H. Ji, Z. Miao, J. Yao, and W. Zhang Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives Bioorg. Med. Chem. Lett. 20 2010 2942 2945
33. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
34. C.K. Chen, P.S. Doyle, L.V. Yermalitskaya, Z.B. Mackey, K.K. Ang, J.H. McKerrow, and L.M. Podust Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit PLoS Negl. Trop. Dis. 3 2009 e372
35. C.K. Chen, S.S. Leung, C. Guilbert, M.P. Jacobson, J.H. McKerrow, and L.M. Podust Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole PLoS Negl. Trop. Dis. 4 2010 e651
36. T.Y. Hargrove, Z. Wawrzak, J. Liu, W.D. Nes, M.R. Waterman, and G.I. Lepesheva Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum J. Biol. Chem. 286 2011 26838 26848
37. G.I. Lepesheva, T.Y. Hargrove, S. Anderson, Y. Kleshchenko, V. Furtak, Z. Wawrzak, F. Villalta, and M.R. Waterman Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi J. Biol. Chem. 285 2010 25582 25590
38. G.I. Lepesheva, H.W. Park, T.Y. Hargrove, B. Vanhollebeke, Z. Wawrzak, J.M. Harp, M. Sundaramoorthy, W.D. Nes, E. Pays, M. Chaudhuri, F. Villalta, and M.R. Waterman Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections J. Biol. Chem. 285 2010 1773 1780
39. L.M. Podust, T.L. Poulos, and M.R. Waterman Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors Proc. Natl. Acad. Sci. U.S.A. 98 2001 3068 3073
40. N. Strushkevich, S.A. Usanov, and H.W. Park Structural basis of human CYP51 inhibition by antifungal azoles J. Mol. Biol. 397 2010 1067 1078
41. R. Thomsen, and M.H. Christensen MolDock: a new technique for high-accuracy molecular docking J. Med. Chem. 49 2006 3315 3321